0001209191-14-068350.txt : 20141112
0001209191-14-068350.hdr.sgml : 20141111
20141112203743
ACCESSION NUMBER: 0001209191-14-068350
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141109
FILED AS OF DATE: 20141112
DATE AS OF CHANGE: 20141112
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001582313
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 980661854
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
BUSINESS PHONE: (604) 484-3300
MAIL ADDRESS:
STREET 1: 200 - 3650 GILMORE WAY
CITY: BURNABY
STATE: A1
ZIP: V5G 48W
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HOLLER FRANK A
CENTRAL INDEX KEY: 0000938801
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36687
FILM NUMBER: 141216007
MAIL ADDRESS:
STREET 1: SUITE 707
STREET 2: 1177 WEST HASTINGS ST
CITY: VANCOVER BRITISH COL
STATE: A1
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-11-09
0
0001582313
Xenon Pharmaceuticals Inc.
XENE
0000938801
HOLLER FRANK A
C/O XENON PHARMACEUTICALS INC.
200 - 3650 GILMORE WAY
BURNABY
A1
V5G 4W8
BRITISH COLUMBIA, CANADA
1
0
0
0
Common Shares
2014-11-09
4
C
0
95002
A
165893
D
Common Shares
2014-11-09
4
C
0
4988
A
170881
D
Common Shares
2014-11-09
4
C
0
2737
A
173618
D
Common Shares
2014-11-09
4
C
0
941
A
1184
I
By wife
Series A Preferred Shares
2014-11-09
4
C
0
95002
0.00
D
Common Shares
95002
0
D
Series A Preferred Shares
2014-11-09
4
C
0
941
0.00
D
Common Shares
941
0
I
By wife
Series B Preferred Shares
2014-11-09
4
C
0
4988
0.00
D
Common Shares
4988
0
D
Series E Preferred Shares
2014-11-09
4
C
0
2737
0.00
D
Common Shares
2737
0
D
The Series A Preferred Shares and Series B Preferred Shares converted into Common Shares on a 1-for-1 basis immediately prior to the completion of the Issuer's initial public offering of Common Shares and had no expiration date.
The Series E Preferred Shares converted into Common Shares on a 1.2-for-1 basis immediately prior to the completion of the Issuer's initial public offering of Common Shares and had no expiration date.
/s/ Barbara A. Mery, Attorney-in-fact
2014-11-12